risperidone [Ligand Id: 96] activity data from GtoPdb and ChEMBL
Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
| ChEMBL ligand: CHEMBL85 (LY-03004, LY03004, N05AX08, NSC-759895, Okedi, Perseris, Perseris kit, R 64 766, R-64,766, R-64-766, R-64766, RCN-3028, RCN3028, Risperdal, Risperdal consta, Risperdal consta long acting, Risperdal m, Risperdal m-tab, Risperdal quicklet, Risperidona, Risperidone, Risvan, Rykindo, Uzedy) |
|---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
| DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
|---|---|---|---|---|---|---|---|---|
| 5-HT1A receptor/5-hydroxytryptamine receptor 1A in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL214] [GtoPdb: 1] [UniProtKB: P08908] | ||||||||
| ChEMBL | Binding affinity to 5HT1A receptor | B | 6.4 | pKd | 398.11 | nM | Kd | J Med Chem (2009) 52: 6107-6125 [PMID:19754201] |
| ChEMBL | Displacement of [3H]-8-OH-DPAT from human 5-HT1AR expressed in HEK293 cell membranes after 1 hr by microbeta counting method | B | 5.93 | pKi | 1169 | nM | Ki | Eur J Med Chem (2018) 145: 790-804 [PMID:29407591] |
| ChEMBL | Binding affinity to serotonin 5-HT1A receptor (unknown origin) by PDSP assay | B | 6 | pKi | 1000 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| GtoPdb | - | - | 6.5 | pKi | - | - | - |
Eur J Pharmacol (1998) 355: 245-56 [PMID:9760039]; Psychopharmacology (Berl.) (1996) 124: 57-73 [PMID:8935801] |
| ChEMBL | Binding affinity to 5HT1A receptor (unknown origin) | B | 6.57 | pKi | 271 | nM | Ki | Bioorg Med Chem Lett (2020) 30: 127506-127506 [PMID:32828898] |
| ChEMBL | Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand | B | 6.6 | pKi | 253 | nM | Ki | Bioorg Med Chem Lett (2001) 11: 2345-2349 [PMID:11527728] |
| ChEMBL | Displacement of [3H]8-OH-DPAT from human 5HT1A receptor expressed in CHO cells | B | 6.6 | pKi | 251.19 | nM | Ki | J Med Chem (2007) 50: 5103-5108 [PMID:17880057] |
| ChEMBL | Binding affinity to human cloned 5HT1A receptor | B | 6.68 | pKi | 210 | nM | Ki | Bioorg Med Chem (2008) 16: 7291-7301 [PMID:18595716] |
| ChEMBL | Binding affinity to 5HT1A receptor (unknown origin) | B | 6.72 | pKi | 190 | nM | Ki | J Med Chem (2014) 57: 9578-9597 [PMID:25343529] |
| ChEMBL | Binding affinity to 5-HT1A receptor (unknown origin) | B | 6.74 | pKi | 182 | nM | Ki | Bioorg Med Chem Lett (2021) 40: 127909-127909 [PMID:33705900] |
| ChEMBL | Binding affinity towards human 5-hydroxytryptamine 1 receptor | B | 7.68 | pKi | 21 | nM | Ki | J Med Chem (2001) 44: 477-501 [PMID:11170639] |
| ChEMBL | 5-HT1A Receptor Agonism Activity Test: The 5-HT1A receptor agonism activity test (The agonism activity of test compounds on 5-HT1A receptor expressing human recombinant 5-HT1A receptor in HEK293 cells) was performed using LANCE cAMP 384 Kit (Product of USA PerkinElmer Inc.). The 5-HT1A receptor agonism activity of test compounds was evaluated through their inhibition on cAMP production in HEK293 cells. cAMP concentration test was performed according to the method documented in the kit instructions. The concentration of the test compounds was 0.1 nM-10000 nM, 8-OH-DPAT was used as a positive control, EC50 value was calculated by the Excelfit software. | B | 4 | pEC50 | >100000 | nM | EC50 | US-10174011-B2. Heterocyclic compounds, process for preparation of the same and use thereof (2019) |
| ChEMBL | Agonist activity at 5-HT1A receptor (unknown origin) after 60 mins by Ultra lance cAMP assay | F | 5 | pEC50 | >10000 | nM | EC50 | Bioorg Med Chem (2017) 25: 4904-4916 [PMID:28774576] |
| 5-HT1A receptor/5-hydroxytryptamine receptor 1A in Mouse (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3737] [GtoPdb: 1] [UniProtKB: Q64264] | ||||||||
| ChEMBL | Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice. | B | 6.37 | pIC50 | 430 | nM | IC50 | J Med Chem (1996) 39: 4692-4703 [PMID:8941382] |
| 5-HT1A receptor/5-hydroxytryptamine receptor 1A in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL273] [GtoPdb: 1] [UniProtKB: P19327] | ||||||||
| ChEMBL | The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M. | B | 6.14 | pKi | 720 | nM | Ki | J Med Chem (1999) 42: 3342-3355 [PMID:10464021] |
| GtoPdb | - | - | 6.2 | pKi | - | - | - | Eur J Pharmacol (1996) 317: 417-23 [PMID:8997630] |
| ChEMBL | Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding. | B | 6.31 | pKi | 491 | nM | Ki | J Med Chem (1998) 41: 5402-5409 [PMID:9876110] |
| ChEMBL | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT) | B | 6.34 | pKi | 457 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex | B | 6.6 | pKi | 253 | nM | Ki | J Med Chem (1998) 41: 1997-2009 [PMID:9622541] |
| ChEMBL | Displacement of [3H]8-OH-DPAT from 5-HT1A receptor in rat cerebral cortex homogenates after 60 mins by liquid scintillation counting | B | 6.68 | pKi | 211 | nM | Ki | Bioorg Med Chem Lett (2015) 25: 5299-5305 [PMID:26483200] |
| ChEMBL | Displacement of [3H]8-OH-DPAT from 5HT1A receptor in Sprague-Dawley rat brain cortex homogenate after 30 mins by liquid scintillation counting | B | 6.72 | pKi | 190.2 | nM | Ki | Eur J Med Chem (2014) 74: 427-439 [PMID:24487191] |
| ChEMBL | Displacement of [3H]8-OH-DPAT from 5HT1A receptor in rat brain cortex | B | 6.72 | pKi | 190.2 | nM | Ki | Medchemcomm (2015) 6: 831-838 |
| ChEMBL | Displacement of [3H]8OH-DPAT from 5HT1A receptor in CRL:CD(SD)BR-COBS rat hippocampus by scintillation spectrometry | B | 6.72 | pKi | 190 | nM | Ki | J Med Chem (2009) 52: 151-169 [PMID:19072656] |
| ChEMBL | Displacement of [3H]8-OH-DPAT from 5-HT1A receptor in Sprague-Dawley rat cerebral cortex incubated for 30 mins by liquid scintillation counting analysis | B | 6.74 | pKi | 182 | nM | Ki | Eur J Med Chem (2016) 124: 713-728 [PMID:27639363] |
| ChEMBL | Displacement of [3H](+)8-OH-DPAT from rat cerebral cortex 5HT1A receptor measured after 30 mins by liquid scintillation counting method | B | 6.74 | pKi | 182 | nM | Ki | Eur J Med Chem (2020) 207: 112709-112709 [PMID:32877805] |
| ChEMBL | Displacement of [3H]-8-OH-DPAT from serotonin 5-HT1A receptor in rat brain cortex homogenates incubated for 30 mins by liquid scintillation counting | B | 6.74 | pKi | 181.9 | nM | Ki | J Med Chem (2018) 61: 10017-10039 [PMID:30383372] |
| ChEMBL | Displacement of [3H]8-OH-DPAT from 5HT1A receptor in rat cerebral cortex after 30 mins by liquid scintillation counting analysis | B | 6.74 | pKi | 180 | nM | Ki | J Med Chem (2013) 56: 4671-4690 [PMID:23675993] |
| ChEMBL | Receptor Binding Assay: 5-HT1A: (1) The prepared membrane was applied with appropriate amount of buffer, and homogenizer was used for evenly dispersing. 15 tubes were mixed into a 100 ml container, and appropriate amount of buffer was added to give 50 ml of membrane suspension, which was reserved for future use. (2) 100 μL of membrane preparation and 100 μL of buffer were added into each reaction tube. (3) 100 μL of buffer was added into the total binding tube (TB), 100 μL of 5-HT (final concentration 10-5M) was added into the nonspecific binding tube (NB), 100 μL of the test compound (final concentration 10-5M) was added into the specific binding tube (SB) of each test compound. (4) 10 μL of radioactive ligand 3H-8-OH-DPAT was respectively added into each reaction tube (2 parallel tubes were used for each reaction tube, and each of them was placed on ice when adding sample). (5) Each reaction tube was incubated at 37° C. for 10 min; after the reaction was completed, the bound ligands were rapidly filtered under reduced pressure, and sufficiently washed with ice-chilled assay buffer. The filter was taken out and put into a 3 ml scintillation vial, and 2 ml of toluene scintillation cocktail was added and blended. | B | 6.77 | pKi | 171 | nM | Ki | US-10501452-B2. Lactam compound derivative and application thereof (2019) |
| ChEMBL | Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor | B | 6.89 | pKi | 130 | nM | Ki | Bioorg Med Chem Lett (1995) 5: 1245-1250 |
| ChEMBL | In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus | B | 6.02 | pIC50 | 950 | nM | IC50 | J Med Chem (1994) 37: 2308-2314 [PMID:7914536] |
| ChEMBL | Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand | B | 6.02 | pIC50 | 950 | nM | IC50 | J Med Chem (1996) 39: 4044-4057 [PMID:8831770] |
| ChEMBL | Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue | B | 6.09 | pIC50 | 820 | nM | IC50 | J Med Chem (1991) 34: 1068-1072 [PMID:1672156] |
| ChEMBL | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT) | B | 6.1 | pIC50 | 799 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| 5-HT1B receptor/5-hydroxytryptamine receptor 1B in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1898] [GtoPdb: 2] [UniProtKB: P28222] | ||||||||
| GtoPdb | - | - | 7.3 | pKi | - | - | - |
Psychopharmacology (Berl.) (1996) 124: 57-73 [PMID:8935801]; Br J Pharmacol (1998) 123: 1655-65 [PMID:9605573]; J Psychopharmacol (Oxford) (2009) 23: 65-73 [PMID:18308814] |
| ChEMBL | Binding affinity to serotonin 5-HT1B receptor (unknown origin) by PDSP assay | B | 8 | pKi | 10 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| 5-HT1D receptor/5-hydroxytryptamine receptor 1D in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1983] [GtoPdb: 3] [UniProtKB: P28221] | ||||||||
| ChEMBL | Binding affinity to serotonin 5-HT1D receptor (unknown origin) by PDSP assay | B | 6 | pKi | 1000 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| GtoPdb | - | - | 8 | pKi | - | - | - |
Psychopharmacology (Berl.) (1996) 124: 57-73 [PMID:8935801]; Mol Pharmacol (1996) 50: 1567-80 [PMID:8967979] |
| 5-ht1e receptor/5-hydroxytryptamine receptor 1E in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2182] [GtoPdb: 4] [UniProtKB: P28566] | ||||||||
| GtoPdb | - | - | 5.9 | pKi | - | - | - | Psychopharmacology (Berl.) (1996) 124: 57-73 [PMID:8935801] |
| ChEMBL | Binding affinity to serotonin 5-HT1E receptor (unknown origin) by PDSP assay | B | 6 | pKi | >1000 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| 5-HT2A receptor/5-hydroxytryptamine receptor 2A in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL224] [GtoPdb: 6] [UniProtKB: P28223] | ||||||||
| ChEMBL | Binding affinity to serotonin 5-HT2A receptor (unknown origin) by PDSP assay | B | 9 | pKi | <1 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| ChEMBL | Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis | B | 9 | pKi | 1 | nM | Ki | J Med Chem (2014) 57: 4543-4557 [PMID:24805037] |
| ChEMBL | Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHO cells | B | 9 | pKi | 1 | nM | Ki | J Med Chem (2007) 50: 5103-5108 [PMID:17880057] |
| ChEMBL | Inhibition of [125I]R91150 binding to human 5-hydroxytryptamine 2A receptor | B | 9.09 | pKi | 0.81 | nM | Ki | J Med Chem (2005) 48: 1709-1712 [PMID:15771415] |
| ChEMBL | Displacement of [3H]ketanserin from human 5-HT2A receptor | B | 9.3 | pKi | 0.5 | nM | Ki | Eur J Med Chem (2014) 71: 237-249 [PMID:24316025] |
| ChEMBL | Displacement of [3H]ketanserin human cloned serotonin 5HT2A receptor | B | 9.3 | pKi | 0.5 | nM | Ki | Bioorg Med Chem Lett (2007) 17: 4873-4877 [PMID:17588750] |
| ChEMBL | Displacement of [3H]ketanserin from human cloned 5-HT2A receptor by in vitro binding assay | B | 9.3 | pKi | 0.5 | nM | Ki | Medchemcomm (2011) 2: 1194-1200 |
| ChEMBL | Displacement of [3H]ketanserin from human cloned 5HT2A receptor | B | 9.3 | pKi | 0.5 | nM | Ki | Bioorg Med Chem Lett (2009) 19: 6059-6062 [PMID:19796944] |
| ChEMBL | Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor | B | 9.3 | pKi | 0.5 | nM | Ki | Bioorg Med Chem Lett (2004) 14: 585-589 [PMID:14741248] |
| ChEMBL | Binding Assay: Binding assay using 5-HT2A, Dopamine D2, SERT, αA1, 5-HT2C and H1 Receptors. | B | 9.3 | pKi | 0.5 | nM | Ki | US-8598119-B2. Methods and compositions for sleep disorders and other disorders (2013) |
| ChEMBL | Binding Assay: Binding assay using 5-HT2A, Dopamine D2, SERT, αA1, 5-HT2C and H1 Receptors. | B | 9.3 | pKi | 0.5 | nM | Ki | US-8598119-B2. Methods and compositions for sleep disorders and other disorders (2013) |
| ChEMBL | Displacement of [3H]-ketanserin from human 5-HT2AR expressed in CHO-K1 cell membranes after 1.5 hrs by microbeta counting method | B | 9.3 | pKi | 0.5 | nM | Ki | Eur J Med Chem (2018) 145: 790-804 [PMID:29407591] |
| ChEMBL | Binding affinity for human 5-hydroxytryptamine 2A receptor | B | 9.41 | pKi | 0.39 | nM | Ki | J Med Chem (2001) 44: 477-501 [PMID:11170639] |
| ChEMBL | Binding affinity to 5HT2A receptor (unknown origin) | B | 9.41 | pKi | 0.39 | nM | Ki | Bioorg Med Chem Lett (2020) 30: 127506-127506 [PMID:32828898] |
| ChEMBL | Displacement of [3H]ketanserin from human 5HT2A receptor expressed in HEK293 cell membranes measured after 30 mins | B | 9.43 | pKi | 0.37 | nM | Ki | Eur J Med Chem (2019) 180: 673-689 [PMID:31357129] |
| ChEMBL | Binding affinity to human cloned 5HT2A receptor | B | 9.54 | pKi | 0.29 | nM | Ki | Bioorg Med Chem (2008) 16: 7291-7301 [PMID:18595716] |
| ChEMBL | Displacement of [3H]-ketanserin from human 5-HT2A receptor expressed in CHO-K1 cells membrane incubated for 1 hr by microbeta liquid scintillation counting analysis | B | 9.64 | pKi | 0.23 | nM | Ki | Eur J Med Chem (2023) 252: 115285-115285 [PMID:37027998] |
| ChEMBL | Binding affinity to 5-HT2A receptor (unknown origin) | B | 9.72 | pKi | 0.19 | nM | Ki | Bioorg Med Chem Lett (2021) 40: 127909-127909 [PMID:33705900] |
| ChEMBL | Antagonist activity at 5HT2A receptor (unknown origin) | B | 9.77 | pKi | 0.17 | nM | Ki | Eur J Med Chem (2020) 193: 112214-112214 [PMID:32182489] |
| ChEMBL | Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor | B | 9.8 | pKi | 0.16 | nM | Ki | J Med Chem (2004) 47: 1303-1314 [PMID:14998318] |
| ChEMBL | Binding affinity to 5HT2A receptor (unknown origin) | B | 9.82 | pKi | 0.15 | nM | Ki | J Med Chem (2014) 57: 9578-9597 [PMID:25343529] |
| GtoPdb | - | - | 10 | pKi | - | - | - |
Psychopharmacology (Berl.) (1996) 124: 57-73 [PMID:8935801]; Neuropsychopharmacology (2003) 28: 519-26 [PMID:12629531]; Eur J Pharmacol (2002) 450: 37-41 [PMID:12176106] |
| ChEMBL | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin) | B | 10 | pKi | 0.1 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | Antagonist activity at 5-HT2A receptor (unknown origin) after 10 mins by calcium 5 dye based FLIPR assay | F | 8.33 | pIC50 | 4.67 | nM | IC50 | Bioorg Med Chem (2017) 25: 4904-4916 [PMID:28774576] |
| ChEMBL | 5-HT2A Receptor Antagonism Activity Test: The 5-HT2A receptor antagonism activity test (The antagonism activity of test compounds on 5-HT2A receptor expressing human recombinant 5-HT2A receptor in CHO-K1 cells) was performed using FLIPR Calcium 5 Assay Kit (Product of Molecular Devices USA Inc.) according to the method documented in the kit instructions. The concentration of the test compounds was 0.1 nM-10000 nM and risperidone was used as a positive control. Test method is as follows: On the first day the seed cells are placed in T-175 flask containing 25 ml growth medium (F-12 nutrient mixture+10% FBS+1% penicillin/streptomycin+1.2% 50 mg/ml Geneticin) at a density of 14 million per bottle, cells were cultured under 37° C./5% CO2/humidified conditions for 24 hours; On the next day the seed cells were inoculated to the 384-well cell culture plate (each well containing 20,000 cells), the growth medium was replaced by 50 μL detecting medium (F-12 nutrient mixture+1.5% activated carbon-treated FBS), the cells were cultured under 37° C./5% CO2/humidified conditions for 16 hours; On the third day the medium was removed, each well of the cells plates were added with 24 μL freshly prepared loading dye solution (formulated according to the instructions), the plates were placed in an incubator and incubated under 37° C./5% CO2/humidified conditions for 120 minutes; transfer 6 μL test compound solution to the assay plate and gently shaking for one minute, incubated under 37° C./5% CO2/humidified conditions for 30 minutes; each well of the assay plate was added with 10 μL freshly prepared α-methyl-5-hydroxytryptamine solution (1.2 M, the final concentration of α-methyl-5-hydroxytryptamine is 300 nM), data were detected and analyzed by FLIPR (Product of US Molecular Devices Corporation). Inhibition rate of the compounds at different concentrations was calculated, IC50 value was calculated by the Excelfit software | B | 8.33 | pIC50 | 4.67 | nM | IC50 | US-10174011-B2. Heterocyclic compounds, process for preparation of the same and use thereof (2019) |
| ChEMBL | Antagonist activity at human 5HT2A receptor expressed in CHOK1 cells assessed as inhibition of 5-HT induced inositol phosphate production incubated for 24 hrs followed by 5-HT addition by HTRF assay | F | 9.14 | pIC50 | 0.72 | nM | IC50 | Eur J Med Chem (2019) 180: 673-689 [PMID:31357129] |
| ChEMBL | Antagonist activity at human 5HT2A receptor expressed in CHOK1 cells assessed as inhibition of 5-HT induced inositol phosphate production incubated for 24 hrs followed by 5-HT addition by HTRF assay | F | 9.15 | pIC50 | 0.71 | nM | IC50 | Eur J Med Chem (2019) 180: 673-689 [PMID:31357129] |
| ChEMBL | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin) | B | 9.46 | pIC50 | 0.35 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| 5-HT2A receptor/5-hydroxytryptamine receptor 2A in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL322] [GtoPdb: 6] [UniProtKB: P14842] | ||||||||
| ChEMBL | Receptor Binding Assay: 5-HT2A:(1) The prepared membrane was applied with buffer, and homogenizer was used for evenly dispersing. 15 tubes were mixed into a 100 ml container, and appropriate amount of buffer was added to give 50 ml of membrane suspension, which was reserved for future use.(2) 100 μL of membrane preparation and 100 μL of buffer were added into each reaction tube.(3) 100 μL of buffer was added into the total binding tube (TB), 100 μL of Methysergide (final concentration 10−5M) was added into the nonspecific binding tube (NB), 100 μL of the test compound (final concentration 10−5M) was added into the specific binding tube (SB) of each test compound.(4) 10 μL of radioactive ligand 3H-Ketanserin was respectively added into each reaction tube (2 parallel tubes were used for each reaction tube, and each of them was placed on ice when adding sample).(5) Each of the reaction tubes was incubated at 37° C. for 15 min. After the reaction was completed, the bound ligands were rapidly filtered under reduced pressure, and sufficiently washed with ice-chilled assay buffer. The filter was taken out and put into a 3 ml scintillation vial, and 2 ml of toluene scintillation cocktail was added and blended.(6) The scintillation vial were put into Liquid Scintillation Counter for counting.Inhibition rate(I%)=(Total binding tube cpm−compound cpm)/(Total binding tube cpm−nonspecific binding tube cpm)×100% . | B | 8.45 | pKi | 3.55 | nM | Ki | US-10501452-B2. Lactam compound derivative and application thereof (2019) |
| GtoPdb | - | - | 8.5 | pKi | - | - | - | J Pharmacol Exp Ther (1998) 286: 85-90 [PMID:9655845] |
| ChEMBL | Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding. | B | 9.15 | pKi | 0.7 | nM | Ki | J Med Chem (1998) 41: 5402-5409 [PMID:9876110] |
| ChEMBL | Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor | B | 9.27 | pKi | 0.54 | nM | Ki | J Med Chem (1996) 39: 143-148 [PMID:8568801] |
| ChEMBL | Displacement of [3H]ketanserine from 5-HT2A receptor in rat cerebral cortex homogenates after 60 mins by liquid scintillation counting | B | 9.51 | pKi | 0.31 | nM | Ki | Bioorg Med Chem Lett (2015) 25: 5299-5305 [PMID:26483200] |
| ChEMBL | Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex | B | 9.51 | pKi | 0.31 | nM | Ki | J Med Chem (2002) 45: 54-71 [PMID:11754579] |
| ChEMBL | In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor | B | 9.51 | pKi | 0.31 | nM | Ki | J Med Chem (2000) 43: 4678-4693 [PMID:11101359] |
| ChEMBL | Displacement of [3H]Ketanserin from 5HT2A receptor in Sprague-Dawley rat brain cortex homogenate after 30 mins by liquid scintillation counting | B | 9.6 | pKi | 0.25 | nM | Ki | Eur J Med Chem (2014) 74: 427-439 [PMID:24487191] |
| ChEMBL | Displacement of [3H]ketanserin from 5HT2A receptor in rat brain cortex | B | 9.6 | pKi | 0.25 | nM | Ki | Medchemcomm (2015) 6: 831-838 |
| ChEMBL | In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane. | B | 9.7 | pKi | 0.2 | nM | Ki | J Med Chem (1999) 42: 2774-2797 [PMID:10425088] |
| ChEMBL | Displacement of [3H]ketanserin from rat cerebral cortex 5HT2A receptor measured after 15 mins by liquid scintillation counting method | B | 9.72 | pKi | 0.19 | nM | Ki | Eur J Med Chem (2020) 207: 112709-112709 [PMID:32877805] |
| ChEMBL | Displacement of [3H] ketanserin from 5-HT2A receptor in Sprague-Dawley rat cerebral cortex incubated for 30 mins by liquid scintillation counting analysis | B | 9.74 | pKi | 0.18 | nM | Ki | Eur J Med Chem (2016) 124: 713-728 [PMID:27639363] |
| ChEMBL | Displacement of [3H]ketanserin from 5HT2A receptor in rat cerebral cortex after 15 mins by liquid scintillation counting analysis | B | 9.74 | pKi | 0.18 | nM | Ki | J Med Chem (2013) 56: 4671-4690 [PMID:23675993] |
| ChEMBL | Displacement of [3H]-ketanserine from serotonin 5-HT2A receptor in rat brain cortex homogenates incubated for 30 mins by liquid scintillation counting | B | 9.74 | pKi | 0.18 | nM | Ki | J Med Chem (2018) 61: 10017-10039 [PMID:30383372] |
| ChEMBL | Displacement of [3H]ketanserin from 5HT2A receptor in rat brain | B | 9.8 | pKi | 0.16 | nM | Ki | Bioorg Med Chem (2007) 15: 7361-7367 [PMID:17869521] |
| ChEMBL | Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor. | B | 9.8 | pKi | 0.16 | nM | Ki | J Med Chem (1995) 38: 708-714 [PMID:7861418] |
| ChEMBL | Displacement of [3H]ketanserin from 5HT2A receptor in CRL:CD(SD)BR-COBS rat cortex by scintillation spectrometry | B | 9.82 | pKi | 0.15 | nM | Ki | J Med Chem (2009) 52: 151-169 [PMID:19072656] |
| ChEMBL | In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex | B | 8.59 | pIC50 | 2.6 | nM | IC50 | J Med Chem (1994) 37: 2308-2314 [PMID:7914536] |
| ChEMBL | Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor | B | 8.85 | pIC50 | 1.4 | nM | IC50 | J Med Chem (1998) 41: 5402-5409 [PMID:9876110] |
| 5-HT2B receptor/5-hydroxytryptamine receptor 2B in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1833] [GtoPdb: 7] [UniProtKB: P41595] | ||||||||
| ChEMBL | Displacement of [3H]-5HT from human 5-HT2B receptor assessed as inhibition constant | B | 7.54 | pKi | 29 | nM | Ki | J Med Chem (2023) 66: 11027-11039 [PMID:37584406] |
| ChEMBL | Displacement of [3H]LSD from 5HT2B receptor expressed in CHO cells | B | 7.7 | pKi | 19.95 | nM | Ki | J Med Chem (2007) 50: 5103-5108 [PMID:17880057] |
| ChEMBL | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide) | B | 7.82 | pKi | 15 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide) | B | 7.64 | pIC50 | 23 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| 5-HT2C receptor/5-hydroxytryptamine receptor 2C in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL225] [GtoPdb: 8] [UniProtKB: P28335] | ||||||||
| ChEMBL | Binding affinity to serotonin 5-HT2C receptor (unknown origin) by PDSP assay | B | 7 | pKi | 100 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| ChEMBL | In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus. | B | 7.04 | pKi | 91.2 | nM | Ki | J Med Chem (1999) 42: 2774-2797 [PMID:10425088] |
| ChEMBL | Binding Assay: Binding assay using 5-HT2A, Dopamine D2, SERT, αA1, 5-HT2C and H1 Receptors. | B | 7.2 | pKi | 63 | nM | Ki | US-8598119-B2. Methods and compositions for sleep disorders and other disorders (2013) |
| ChEMBL | Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor | B | 7.2 | pKi | 63 | nM | Ki | J Med Chem (2004) 47: 1303-1314 [PMID:14998318] |
| ChEMBL | Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus | B | 7.38 | pKi | 41.69 | nM | Ki | J Med Chem (2002) 45: 54-71 [PMID:11754579] |
| ChEMBL | In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor | B | 7.38 | pKi | 41.69 | nM | Ki | J Med Chem (2000) 43: 4678-4693 [PMID:11101359] |
| ChEMBL | Displacement of [3H]mesulergine from human 5HT2C receptor in human tsA201 cells | B | 7.48 | pKi | 33 | nM | Ki | Bioorg Med Chem Lett (2010) 20: 5431-5433 [PMID:20719507] |
| ChEMBL | Binding affinity to 5HT2C receptor (unknown origin) | B | 7.49 | pKi | 32 | nM | Ki | J Med Chem (2014) 57: 9578-9597 [PMID:25343529] |
| GtoPdb | - | - | 7.6 | pKi | - | - | - |
Neuropsychopharmacology (2003) 28: 519-26 [PMID:12629531]; J Pharmacol Exp Ther (2000) 295: 226-32 [PMID:10991983] |
| ChEMBL | Displacement of [3H]mesulergine from 5HT2C receptor expressed in CHO cells | B | 7.9 | pKi | 12.59 | nM | Ki | J Med Chem (2007) 50: 5103-5108 [PMID:17880057] |
| ChEMBL | Inhibition of [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor | B | 7.92 | pKi | 12 | nM | Ki | J Med Chem (2005) 48: 1709-1712 [PMID:15771415] |
| ChEMBL | Binding affinity to human cloned 5HT2C receptor | B | 8 | pKi | 10 | nM | Ki | Bioorg Med Chem (2008) 16: 7291-7301 [PMID:18595716] |
| ChEMBL | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine) | B | 8.12 | pKi | 7.64 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | Displacement of [3H]mesulergine human cloned serotonin 5HT2C receptor | B | 8.13 | pKi | 7.41 | nM | Ki | Bioorg Med Chem Lett (2007) 17: 4873-4877 [PMID:17588750] |
| ChEMBL | Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor | B | 8.13 | pKi | 7.41 | nM | Ki | Bioorg Med Chem Lett (2004) 14: 585-589 [PMID:14741248] |
| ChEMBL | Displacement of [3H]mesulergine from human 5HT2C receptor | B | 8.13 | pKi | 7.41 | nM | Ki | Bioorg Med Chem Lett (2009) 19: 6059-6062 [PMID:19796944] |
| ChEMBL | Binding affinity towards human 5-hydroxytryptamine 2C receptor | B | 8.19 | pKi | 6.4 | nM | Ki | J Med Chem (2001) 44: 477-501 [PMID:11170639] |
| ChEMBL | Displacement of [3H]-Mesulergine from human 5-HT2C expressed in HeLa cells membrane incubated for 1 hr by microbeta liquid scintillation counting analysis | B | 8.61 | pKi | 2.43 | nM | Ki | Eur J Med Chem (2023) 252: 115285-115285 [PMID:37027998] |
| ChEMBL | DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine) | B | 7.82 | pIC50 | 15 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| ChEMBL | Antagonistic activity at 5-HT2c receptor (unknown origin) after 10 mins by FLIPR assay | B | 8.15 | pIC50 | 7 | nM | IC50 | Bioorg Med Chem Lett (2016) 26: 3141-3147 [PMID:27173799] |
| ChEMBL | Antagonistic activity at 5-HT2c receptor (unknown origin) after 10 mins by FLIPR assay | F | 8.15 | pIC50 | 7 | nM | IC50 | Bioorg Med Chem Lett (2018) 28: 606-611 [PMID:29395980] |
| ChEMBL | Antagonist activity at 5-HT2C receptor (unknown origin) after 10 mins by calcium 5 dye based FLIPR assay | F | 8.74 | pIC50 | 1.81 | nM | IC50 | Eur J Med Chem (2018) 145: 74-85 [PMID:29324345] |
| 5-HT2C receptor/5-hydroxytryptamine receptor 2C in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL324] [GtoPdb: 8] [UniProtKB: P08909] | ||||||||
| ChEMBL | Displacement of [3H]mesulergine from 5HT2C receptor in rat brain cortex | B | 6.9 | pKi | 125.9 | nM | Ki | Medchemcomm (2015) 6: 831-838 |
| ChEMBL | Displacement of [3H]mesulergine from 5-HT2C receptor in rat cerebral cortex homogenates after 60 mins by liquid scintillation counting | B | 7.52 | pKi | 30.1 | nM | Ki | Bioorg Med Chem Lett (2015) 25: 5299-5305 [PMID:26483200] |
| ChEMBL | Displacement of [3H]-mesulergine from serotonin 5-HT2C receptor in rat brain cerebral cortex homogenates incubated for 15 mins by liquid scintillation counting | B | 7.55 | pKi | 28.2 | nM | Ki | J Med Chem (2018) 61: 10017-10039 [PMID:30383372] |
| ChEMBL | Displacement of [3H]mesulergine from 5HT2C receptor in rat cerebral cortex after 15 mins by liquid scintillation counting analysis | B | 7.84 | pKi | 14.5 | nM | Ki | J Med Chem (2013) 56: 4671-4690 [PMID:23675993] |
| 5-HT3A/5-hydroxytryptamine receptor 3A in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1899] [GtoPdb: 373] [UniProtKB: P46098] | ||||||||
| ChEMBL | Binding affinity to serotonin 5-HT3 receptor (unknown origin) by PDSP assay | B | 6 | pKi | >1000 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| 5-HT5A receptor/5-hydroxytryptamine receptor 5A in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3426] [GtoPdb: 10] [UniProtKB: P47898] | ||||||||
| ChEMBL | Binding affinity to serotonin 5-HT5A receptor (unknown origin) by PDSP assay | B | 6 | pKi | 1000 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| 5-HT6 receptor/5-hydroxytryptamine receptor 6 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3371] [GtoPdb: 11] [UniProtKB: P50406] | ||||||||
| GtoPdb | - | - | 5.6 | pKi | - | - | - | J Neurochem (1996) 66: 47-56 [PMID:8522988] |
| ChEMBL | Binding affinity to human cloned 5HT6 receptor | B | 5.7 | pKi | 2000 | nM | Ki | Bioorg Med Chem (2008) 16: 7291-7301 [PMID:18595716] |
| ChEMBL | Binding affinity to 5-HT6 receptor (unknown origin) | B | 5.88 | pKi | 1329.2 | nM | Ki | Bioorg Med Chem Lett (2021) 40: 127909-127909 [PMID:33705900] |
| ChEMBL | Displacement of [3H]lysergic acid diethylamide from human recombinant 5HT6 receptor stably expressed in CHO cell membranes measured after 30 mins by liquid scintillation counting method | B | 5.88 | pKi | 1329 | nM | Ki | Eur J Med Chem (2020) 207: 112709-112709 [PMID:32877805] |
| ChEMBL | Displacement of [3H]lysergic acid diethylamide from human recombinant 5-HT6 receptor expressed in CHO cell membranes for 30 mins by liquid scintillation counting analysis | B | 5.9 | pKi | 1260 | nM | Ki | Eur J Med Chem (2016) 124: 713-728 [PMID:27639363] |
| ChEMBL | Displacement of [3H]-lysergic acid diethylamide from human serotonin 5-HT6 receptor expressed in CHO cell membranes incubated for 30 mins by liquid scintillation counting | B | 5.9 | pKi | 1260 | nM | Ki | J Med Chem (2018) 61: 10017-10039 [PMID:30383372] |
| ChEMBL | Binding affinity to 5HT6 receptor (unknown origin) | B | 5.92 | pKi | 1190 | nM | Ki | Bioorg Med Chem Lett (2020) 30: 127506-127506 [PMID:32828898] |
| ChEMBL | Displacement of [3H]-LSD from human 5-HT6R expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method | B | 5.96 | pKi | 1107 | nM | Ki | Eur J Med Chem (2018) 145: 790-804 [PMID:29407591] |
| ChEMBL | Binding affinity to serotonin 5-HT6 receptor (unknown origin) by PDSP assay | B | 6 | pKi | >1000 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| ChEMBL | Displacement of [3H]5-LSD from human 5HT6 receptor expressed in human HeLa cells | B | 6.65 | pKi | 224 | nM | Ki | Bioorg Med Chem Lett (2010) 20: 5431-5433 [PMID:20719507] |
| 5-HT6 receptor in Rat [GtoPdb: 11] [UniProtKB: P31388] | ||||||||
| GtoPdb | - | - | 6.4 | pKi | - | - | - |
Eur J Pharmacol (1996) 317: 417-23 [PMID:8997630]; J Pharmacol Exp Ther (1994) 268: 1403-10 [PMID:7908055] |
| 5-HT7 receptor/5-hydroxytryptamine receptor 7 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3155] [GtoPdb: 12] [UniProtKB: P34969] | ||||||||
| ChEMBL | Binding affinity to serotonin 5-HT7 receptor (unknown origin) by PDSP assay | B | 8 | pKi | 10 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| ChEMBL | Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 7 receptor | B | 8.37 | pKi | 4.3 | nM | Ki | J Med Chem (2005) 48: 1709-1712 [PMID:15771415] |
| GtoPdb | - | - | 8.7 | pKi | - | - | - |
Psychopharmacology (Berl) (2005) 179: 461-9 [PMID:15821958]; Br J Pharmacol (1998) 124: 1300-6 [PMID:9720804] |
| ChEMBL | Displacement of [3H]LSD from human 5HT7 receptor expressed in CHO cells | B | 9 | pKi | 1 | nM | Ki | J Med Chem (2007) 50: 5103-5108 [PMID:17880057] |
| ChEMBL | Displacement of [3H]-5-CT from human 5-HT7R expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method | B | 9.4 | pKi | 0.4 | nM | Ki | Eur J Med Chem (2018) 145: 790-804 [PMID:29407591] |
| 5-HT7 receptor/5-hydroxytryptamine receptor 7 in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3223] [GtoPdb: 12] [UniProtKB: P32305] | ||||||||
| GtoPdb | - | - | 9 | pKd | - | - | - |
Eur J Pharmacol (1996) 317: 417-23 [PMID:8997630]; J Pharmacol Exp Ther (1994) 268: 1403-10 [PMID:7908055] |
| ChEMBL | Displacement of [3H]5-CT from rat cerebral cortex 5HT7 receptor measured after 30 mins by liquid scintillation counting method | B | 7.39 | pKi | 40.7 | nM | Ki | Eur J Med Chem (2020) 207: 112709-112709 [PMID:32877805] |
| ChEMBL | Receptor Binding Assay: 5-HT7: (1) The prepared membrane was applied with buffer, and homogenizer was used for evenly dispersing. 15 tubes were mixed into a 100 ml container, and appropriate amount of buffer was added to give 50 ml of membrane suspension, which was reserved for future use. (2) 100 μL of membrane preparation and 100 μL of buffer were added into each reaction tube. (3) 100 μL of buffer was added into the total binding tube (TB), 100 μL of (��)-pindolol (final concentration 10-5M) was added into the nonspecific binding tube (NB), 100 μL of the test compound (final concentration 10-5M) was added into the specific binding tube (SB) of each test compound. (4) 10 μL of radioactive ligand 3H-5-CT was respectively added into each reaction tube (2 parallel tubes were used for each reaction tube, and each of them was placed on ice when adding sample). (5) Each of the reaction tubes was incubated at 25° C. for 120 min. After the reaction was completed, the bound ligands were rapidly filtered under reduced pressure, and sufficiently washed with ice-chilled assay buffer. The filter was taken out and put into a 3 ml scintillation vial, and 2 ml of toluene scintillation cocktail was added and blended. | B | 7.89 | pKi | 12.8 | nM | Ki | US-10501452-B2. Lactam compound derivative and application thereof (2019) |
| ChEMBL | Displacement of [3H]-5-CT from 5-HT7 receptor in rat hypothalamus homogenates after 120 mins by liquid scintillation counting | B | 8.49 | pKi | 3.2 | nM | Ki | Bioorg Med Chem Lett (2015) 25: 5299-5305 [PMID:26483200] |
| ChEMBL | Binding affinity towards rat 5-hydroxytryptamine 7 receptor | B | 8.85 | pKi | 1.4 | nM | Ki | J Med Chem (2003) 46: 2795-2812 [PMID:12825922] |
| α1A-adrenoceptor/Alpha-1A adrenergic receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL229] [GtoPdb: 22] [UniProtKB: P35348] | ||||||||
| ChEMBL | Binding affinity to adrenergic alpha1A receptor (unknown origin) by PDSP assay | B | 8 | pKi | 10 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| ChEMBL | Binding constant measured against Alpha-1A adrenergic receptor in human prostate; ++:moderately active | B | 8.55 | pKi | 2.8 | nM | Ki | Bioorg Med Chem Lett (2005) 15: 657-664 [PMID:15664832] |
| ChEMBL | Binding Assay: Binding assay using 5-HT2A, Dopamine D2, SERT, αA1, 5-HT2C and H1 Receptors. | B | 8.64 | pKi | 2.3 | nM | Ki | US-8598119-B2. Methods and compositions for sleep disorders and other disorders (2013) |
| GtoPdb | - | - | 8.7 | pKi | - | - | - |
Jpn J Pharmacol (2001) 86: 189-95 [PMID:11459121]; Pharmacol Res Perspect (2020) 8: e00602 [PMID:32608144] |
| ChEMBL | Antagonist activity at adrenergic alpha1A receptor (unknown origin) after 10 mins by calcium 5 dye based FLIPR assay | F | 7.96 | pIC50 | 10.9 | nM | IC50 | Eur J Med Chem (2018) 145: 74-85 [PMID:29324345] |
| ChEMBL | Antagonistic activity at alpha-1A adrenergic receptor (unknown origin) after 10 mins by FLIPR assay | B | 8 | pIC50 | 10 | nM | IC50 | Bioorg Med Chem Lett (2016) 26: 3141-3147 [PMID:27173799] |
| ChEMBL | Antagonistic activity at alpha-1A adrenergic receptor (unknown origin) after 10 mins by FLIPR assay | F | 8 | pIC50 | 10 | nM | IC50 | Bioorg Med Chem Lett (2018) 28: 606-611 [PMID:29395980] |
| α1A-adrenoceptor/Alpha-1A adrenergic receptor in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL319] [GtoPdb: 22] [UniProtKB: P43140] | ||||||||
| ChEMBL | Binding affinity measured at the Alpha-1A adrenergic receptor by the inhibition of [3H]prazosin binding to rat cortex using unlabeled WB-4101 for nonspecific binding. | B | 7.89 | pKi | 13 | nM | Ki | J Med Chem (1998) 41: 5402-5409 [PMID:9876110] |
| ChEMBL | Receptor Binding Assay: Alpha-1 receptor binding studies were performed according to the methods described by Greengrass and Bremner (Eur. J. Pharmacol., 55:323-326, 1979) on rat cortical membrane preparation using [3H]-prazosine (0.22-0.37 nM) as ligand. The non-specific binding was determined in the presence of 10 μM phentolamine. | B | 9.06 | pKi | 0.88 | nM | Ki | US-8802672-B2. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands (2014) |
| ChEMBL | DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin) | B | 9.4 | pKi | 0.4 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin) | B | 9 | pIC50 | 0.99 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| α1B-adrenoceptor/Alpha-1B adrenergic receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL232] [GtoPdb: 23] [UniProtKB: P35368] | ||||||||
| GtoPdb | - | - | 8 | pKi | - | - | - |
Jpn J Pharmacol (2001) 86: 189-95 [PMID:11459121]; Pharmacol Res Perspect (2020) 8: e00602 [PMID:32608144] |
| ChEMBL | Binding affinity to adrenergic alpha1B receptor (unknown origin) by PDSP assay | B | 8 | pKi | 10 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| α1B-adrenoceptor/Alpha-1B adrenergic receptor in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL315] [GtoPdb: 23] [UniProtKB: P15823] | ||||||||
| ChEMBL | DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin) | B | 8.97 | pKi | 1.08 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin) | B | 8.71 | pIC50 | 1.95 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| α1D-adrenoceptor/Alpha-1D adrenergic receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL223] [GtoPdb: 24] [UniProtKB: P25100] | ||||||||
| GtoPdb | - | - | 7.4 | pKi | - | - | - | Jpn J Pharmacol (2001) 86: 189-95 [PMID:11459121] |
| ChEMBL | DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin) | B | 8.31 | pKi | 4.91 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin) | B | 8 | pIC50 | 9.99 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| α2A-adrenoceptor/Alpha-2A adrenergic receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1867] [GtoPdb: 25] [UniProtKB: P08913] | ||||||||
| ChEMBL | Binding affinity to adrenergic alpha2A receptor (unknown origin) by PDSP assay | B | 6 | pKi | 1000 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| GtoPdb | - | - | 7.3 | pKi | - | - | - | Pharmacol Res Perspect (2022) 10: e00936 [PMID:35224877] |
| ChEMBL | Binding affinity to alpha2 adrenergic receptor (unknown origin) | B | 7.55 | pKi | 28.2 | nM | Ki | Bioorg Med Chem Lett (2020) 30: 127506-127506 [PMID:32828898] |
| ChEMBL | Inhibition of [3H]rauwolscine binding to Alpha-2A adrenergic receptor | B | 8 | pKi | 10 | nM | Ki | J Med Chem (2005) 48: 1709-1712 [PMID:15771415] |
| ChEMBL | DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) | B | 8.44 | pKi | 3.63 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) | B | 8.01 | pIC50 | 9.67 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| α2A-adrenoceptor/Alpha-2A adrenergic receptor in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL327] [GtoPdb: 25] [UniProtKB: P22909] | ||||||||
| ChEMBL | Binding affinity measured at the Alpha-2 adrenergic receptor by the inhibition of [3H]clonidine binding to rat cortex using unlabeled NAbitartrate for nonspecific binding. | B | 7.6 | pKi | 25 | nM | Ki | J Med Chem (1998) 41: 5402-5409 [PMID:9876110] |
| α2B-adrenoceptor/Alpha-2B adrenergic receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1942] [GtoPdb: 26] [UniProtKB: P18089] | ||||||||
| ChEMBL | Binding affinity to adrenergic alpha2B receptor (unknown origin) by PDSP assay | B | 6 | pKi | 1000 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| ChEMBL | DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine) | B | 7.92 | pKi | 12 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine) | B | 7.59 | pIC50 | 26 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| α2C-adrenoceptor/Alpha-2C adrenergic receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1916] [GtoPdb: 27] [UniProtKB: P18825] | ||||||||
| ChEMBL | Binding affinity to adrenergic alpha2C receptor (unknown origin) by PDSP assay | B | 8 | pKi | 10 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| ChEMBL | Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor | B | 8.49 | pKi | 3.2 | nM | Ki | J Med Chem (2005) 48: 1709-1712 [PMID:15771415] |
| ChEMBL | DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912) | B | 8.86 | pKi | 1.39 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912) | B | 8.02 | pIC50 | 9.56 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| β1-adrenoceptor/Beta-1 adrenergic receptor in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3252] [GtoPdb: 28] [UniProtKB: P18090] | ||||||||
| ChEMBL | Binding affinity measured at the Beta-1 adrenergic receptor by the inhibition of [3H]DHA binding to rat cortex using unlabeled isoprenalin for nonspecific binding. | B | 4.66 | pKi | 22000 | nM | Ki | J Med Chem (1998) 41: 5402-5409 [PMID:9876110] |
| CYP2D6/Cytochrome P450 2D6 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL289] [GtoPdb: 1329] [UniProtKB: P10635] | ||||||||
| ChEMBL | DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) | B | 5.28 | pIC50 | 5273.4 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| D1 receptor/D(1A) dopamine receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2056] [GtoPdb: 214] [UniProtKB: P21728] | ||||||||
| ChEMBL | Binding affinity to dopamine D1 receptor (unknown origin) by PDSP assay | B | 6 | pKi | 1000 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| ChEMBL | Binding affinity towards human Dopamine receptor D1 | B | 6.21 | pKi | 620 | nM | Ki | J Med Chem (2004) 47: 1303-1314 [PMID:14998318] |
| ChEMBL | Binding affinity to human cloned dopamine D1 receptor | B | 6.24 | pKi | 580 | nM | Ki | Bioorg Med Chem (2008) 16: 7291-7301 [PMID:18595716] |
| ChEMBL | DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390) | B | 6.62 | pKi | 240 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | Displacement of [3H]SCH23390 from human dopamine D1 receptor | B | 6.83 | pKi | 147.91 | nM | Ki | Bioorg Med Chem Lett (2009) 19: 6059-6062 [PMID:19796944] |
| ChEMBL | Binding affinity against dopamine receptor D1 | B | 7.68 | pKi | 21 | nM | Ki | J Med Chem (2001) 44: 477-501 [PMID:11170639] |
| ChEMBL | DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390) | B | 6.32 | pIC50 | 479 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| D1 receptor/D(1A) dopamine receptor in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL265] [GtoPdb: 214] [UniProtKB: P18901] | ||||||||
| ChEMBL | Binding affinity measured at the Dopamine receptor D1 by the inhibition of [3H]SCH-23390 binding to rat striatum using unlabeled apomorphine for nonspecific binding. | B | 6.6 | pKi | 251 | nM | Ki | J Med Chem (1998) 41: 5402-5409 [PMID:9876110] |
| ChEMBL | Inhibition of [3H]SCH-23390 binding to rat Dopamine receptor D1 | B | 6.83 | pKi | 147 | nM | Ki | J Med Chem (2005) 48: 1709-1712 [PMID:15771415] |
| ChEMBL | Displacement of [3H]SCH23390 from dopamine D1 receptor in CRL:CD(SD)BR-COBS rat striatum by scintillation spectrometry | B | 7.3 | pKi | 50 | nM | Ki | J Med Chem (2009) 52: 151-169 [PMID:19072656] |
| ChEMBL | Affinity for Dopamine receptor D1 | B | 7.66 | pKi | 22 | nM | Ki | Bioorg Med Chem Lett (1998) 8: 983-988 [PMID:9871525] |
| D5 receptor/D(1B) dopamine receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1850] [GtoPdb: 218] [UniProtKB: P21918] | ||||||||
| ChEMBL | Binding affinity to dopamine D5 receptor (unknown origin) by PDSP assay | B | 6 | pKi | 1000 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| D2 receptor/D(2) dopamine receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL217] [GtoPdb: 215] [UniProtKB: P14416] | ||||||||
| ChEMBL | Receptor Binding Assay: D2:Procedures(1) The prepared membrane was applied with appropriate amount of buffer, and homogenizer was used for evenly dispersing. 15 tubes were mixed into a 100 ml container, and appropriate amount of buffer was added to give 50 ml of membrane suspension, which was reserved for future use.(2) 100 μL of membrane preparation and 100 μL of buffer were added into each reaction tube.(3) 100 μL of buffer was added into the total binding tube (TB), 100 μL of Butaclamol (final concentration 10−5M) was added into the nonspecific binding tube (NB), 100 μL of the test compound (final concentration 10−5M) was added into the specific binding tube (SB) of each test compound.(4) 10 μL of radioactive ligand 3H-Spiperone was respectively added into each reaction tube (2 parallel tubes were used for each reaction tube, and each of them was placed on ice when adding sample).(5) Each of the reaction tubes was incubated at 37° C. for 20 min. After the reaction was completed, the bound ligands were rapidly filtered under reduced pressure, and sufficiently washed with ice-chilled assay buffer. The filter was taken out and put into a 3 ml scintillation vial, and 2 ml of toluene scintillation cocktail was added and blended.(6) The scintillation vials were put into Liquid Scintillation Counter for counting.Inhibition rate(I%)=(Total binding tube cpm−compound cpm)/(Total binding tube cpm−nonspecific binding tube cpm)×100% . | B | 7.94 | pKi | 11.6 | nM | Ki | US-10501452-B2. Lactam compound derivative and application thereof (2019) |
| ChEMBL | Binding affinity to dopamine D2 receptor (unknown origin) by PDSP assay | B | 8 | pKi | 10 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| ChEMBL | DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) | B | 8.18 | pKi | 6.54 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | Inhibition of [3H]-spiperone binding to human Dopamine receptor D2 | B | 8.19 | pKi | 6.4 | nM | Ki | J Med Chem (2005) 48: 1709-1712 [PMID:15771415] |
| ChEMBL | Displacement of [3H]spiperone from human dopamine D2 receptor short form expressed in CHO cells | B | 8.2 | pKi | 6.31 | nM | Ki | J Med Chem (2007) 50: 5103-5108 [PMID:17880057] |
| ChEMBL | Displacement of [3H]spiperone from human cloned D2 receptor by in vitro binding assay | B | 8.21 | pKi | 6.17 | nM | Ki | Medchemcomm (2011) 2: 1194-1200 |
| ChEMBL | Displacement of [3H]spiperone from human cloned dopamine D2 receptor | B | 8.21 | pKi | 6.17 | nM | Ki | Bioorg Med Chem Lett (2009) 19: 6059-6062 [PMID:19796944] |
| ChEMBL | Displacement of [3H]spiperone from human D2 receptor | B | 8.21 | pKi | 6.17 | nM | Ki | Eur J Med Chem (2014) 71: 237-249 [PMID:24316025] |
| ChEMBL | Binding Assay: Binding assay using 5-HT2A, Dopamine D2, SERT, αA1, 5-HT2C and H1 Receptors. | B | 8.23 | pKi | 5.9 | nM | Ki | US-8598119-B2. Methods and compositions for sleep disorders and other disorders (2013) |
| ChEMBL | Binding affinity to dopamine D2 receptor (unknown origin) | B | 8.41 | pKi | 3.9 | nM | Ki | Bioorg Med Chem Lett (2021) 40: 127909-127909 [PMID:33705900] |
| ChEMBL | Binding affinity to D2 receptor (unknown origin) | B | 8.42 | pKi | 3.8 | nM | Ki | Bioorg Med Chem Lett (2020) 30: 127506-127506 [PMID:32828898] |
| ChEMBL | Binding affinity to dopamine D2 receptor (unknown origin) | B | 8.42 | pKi | 3.8 | nM | Ki | J Med Chem (2014) 57: 9578-9597 [PMID:25343529] |
| ChEMBL | Binding affinity towards human Dopamine receptor D2 | B | 8.48 | pKi | 3.3 | nM | Ki | J Med Chem (2004) 47: 1303-1314 [PMID:14998318] |
| ChEMBL | Binding affinity for dopamine receptor D2 determined using [3H]spiperone | B | 8.51 | pKi | 3.1 | nM | Ki | Bioorg Med Chem Lett (2001) 11: 2345-2349 [PMID:11527728] |
| ChEMBL | Displacement of [3H]methylspiperone from human low affinity Dopamine D2S receptor by competition binding assay | B | 8.57 | pKi | 2.7 | nM | Ki | J Med Chem (2012) 55: 9735-9750 [PMID:23043306] |
| ChEMBL | Binding affinity to human cloned dopamine D2 receptor | B | 8.66 | pKi | 2.2 | nM | Ki | Bioorg Med Chem (2008) 16: 7291-7301 [PMID:18595716] |
| ChEMBL | Ability to inhibit the binding of [3H]spiperone to the Dopamine receptor D2L in COS7 cells | B | 8.85 | pKi | 1.4 | nM | Ki | J Med Chem (1995) 38: 708-714 [PMID:7861418] |
| ChEMBL | Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method | B | 9.22 | pKi | 0.6 | nM | Ki | Eur J Med Chem (2018) 145: 790-804 [PMID:29407591] |
| ChEMBL | Binding affinity towards human D2 dopamine receptor. | B | 9.36 | pKi | 0.44 | nM | Ki | J Med Chem (2001) 44: 477-501 [PMID:11170639] |
| GtoPdb | - | - | 9.36 | pKi | 0.44 | nM | Ki | Neuropsychopharmacology (1998) 18: 63-101 [PMID:9430133] |
| ChEMBL | D2 Receptor Agonism Activity Test: The D2 receptor agonism activity test (The agonism activity of test compounds on D2 receptor expressing human recombinant D2 receptor in HEK293 cells) was performed using LANCE cAMP 384 Kit (Product of USA PerkinElmer Inc.). The D2 agonism of test compounds was evaluated through their inhibition on cAMP production in HEK293 cells. cAMP concentration test was performed according to the method documented in the kit instructions. The concentration of the test compound is 0.1 nM-10000 nM, dopamine was used as a positive control, EC50 value was calculated by the Excelfit software. | B | 4 | pIC50 | >100000 | nM | IC50 | US-10174011-B2. Heterocyclic compounds, process for preparation of the same and use thereof (2019) |
| ChEMBL | DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) | B | 7.7 | pIC50 | 20 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| ChEMBL | D2 Receptor Antagonism Activity Test: The D2 receptor antagonism activity test (The antagonism activity of test compounds on D2 receptor expressing human recombinant D2 receptor in HEK293 cells) was performed using LANCE cAMP 384 Kit (Product of USA PerkinElmer Inc.). The D2 antagonism activity of test compounds was evaluated through their inhibition on dopamine-induced decrease of cAMP production in HEK293 cells. cAMP concentration test was performed according to the method documented in the kit instructions. The concentration of the test compounds was 0.1 nM-10000 nM, risperidone was used as a positive control, IC50 value was calculated by the Excelfit software | B | 7.88 | pIC50 | 13.3 | nM | IC50 | US-10174011-B2. Heterocyclic compounds, process for preparation of the same and use thereof (2019) |
| ChEMBL | Binding of Compound 102 to Dopamine D2 Receptors (Membrane Preparation): The ability of Compound 102 to bind the dopamine D2 receptor in a membrane preparation was examined. Medium was removed from dopamine D2 receptor cells and washed with PBS. A lysis buffer (250 mM sucrose, 1 nM EDTA, 10 mM Tris HCl buffered at pH 7.2 plus protease inhibitors) was added and cells scrapped using a plate scrapper. Cells were homogenized with 20 manual up and down strokes in a glass homogenizer. Intact cells, nuclei, and cell debris were removed by centrifugation of the homogenate at 500× g for 10 minutes at 4° C., the supernatant was removed, and the pellet resuspended in assay buffer. Membrane preparations were incubated with 3H spiperone until equilibration. Separation of bound from free radioligand was carried out using a Packard Filtermate Harvester and glass filter plates. Radioactivity was measured using a Packard Topcount. To 20 μL of D2 membranes were mixed 20 μL of 3H spiperone and 10 μL test compound or reference ligand in binding buffer in a nonbinding 96 well plate, and incubated for <120 minutes. Prior to filtration, a 96 well harvest filter plate was coated with 0.33% polyethyleneimine for 30 minutes and then washed with assay buffer. The binding reaction was transferred to the filter plate and washed three times with wash buffer, dried, scintillant added, and radioactivity counted on a Topcount NXT. | B | 7.98 | pIC50 | 10.4 | nM | IC50 | US-10167256-B2. Psychotrophic agents and uses thereof (2019) |
| ChEMBL | Binding of Compound 102 to Dopamine D2 Receptors (Membrane Preparation): The ability of Compound 102 to bind the dopamine D2 receptor in a membrane preparation was examined. Medium was removed from dopamine D2 receptor cells and washed with PBS. A lysis buffer (250 mM sucrose, 1 nM EDTA, 10 mM Tris HCl buffered at pH 7.2 plus protease inhibitors) was added and cells scrapped using a plate scrapper. Cells were homogenized with 20 manual up and down strokes in a glass homogenizer. Intact cells, nuclei, and cell debris were removed by centrifugation of the homogenate at 500×g for 10 minutes at 4° C., the supernatant was removed, and the pellet resuspended in assay buffer.Membrane preparations were incubated with 3H spiperone until equilibration. Separation of bound from free radioligand was carried out using a Packard Filtermate Harvester and glass filter plates. Radioactivity was measured using a Packard Topcount. To 20 μL of D2 membranes were mixed 20 μL of 3H spiperone and 10 μL test compound or reference ligand in binding buffer in a nonbinding 96 well plate, and incubated for <120 minutes. Prior to filtration, a 96 well harvest filter plate was coated with 0.33% polyethyleneimine for 30 minutes and then washed with assay buffer. The binding reaction was transferred to the filter plate and washed three times with wash buffer, dried, scintillant added, and radioactivity counted on a Topcount NXT. | B | 7.98 | pIC50 | 10.4 | nM | IC50 | US-10259786-B2. Psychotropic agents and uses thereof (2019) |
| ChEMBL | Antagonist activity at dopamine D2 receptor (unknown origin) after 60 mins by Ultra lance cAMP assay | F | 8.15 | pIC50 | 7.09 | nM | IC50 | Bioorg Med Chem (2017) 25: 4904-4916 [PMID:28774576] |
| ChEMBL | Dopamine D2 Receptors (Cell-Based Assay): The ability of Compound 102 to bind dopamine D2 receptors was measured in a cell-based assay. Dopamine D2 receptor cells were seeded in a half a black, clear-bottomed 96 well plate. At a density of 15,000 cells/well to a volume of 25 μL and were left to incubate overnight. Calcium 5 dye in HEPES buffered HBSS (Hanks' balanced salt solution) was prepared and 10 μL was added to each well and the mixture was left to sit at 37° C. for 1 hour. After equilibration, 5 μL of the test compound and controls were added to the wells and incubated at room temperature for 10 minutes. Fluorescence was measured every 1.52 seconds. After 20 seconds 10 μL of dopamine (at EC80 concentration) was added and the fluorescence monitored for 2 minutes with excitation at 452 nm and emission at 525 nm. | B | 8.44 | pIC50 | 3.6 | nM | IC50 | US-10167256-B2. Psychotrophic agents and uses thereof (2019) |
| ChEMBL | Binding of Compound 102 to Dopamine D2 Receptors (Cell-Based Assay): The ability of Compound 102 to bind dopamine D2 receptors was measured in a cell-based assay. Dopamine D2 receptor cells were seeded in a half a black, clear-bottomed 96 well plate. At a density of 15,000 cells/well to a volume of 25 μL and were left to incubate overnight. Calcium 5 dye in HEPES buffered HBSS (Hanks' balanced salt solution) was prepared and 10 μL was added to each well and the mixture was left to sit at 37° C. for 1 hour. After equilibration, 5 μL of the test compound and controls were added to the wells and incubated at room temperature for 10 minutes. Fluorescence was measured every 1.52 seconds. After 20 seconds 10 μL of dopamine (at EC80 concentration) was added and the fluorescence monitored for 2 minutes with excitation at 452 nm and emission at 525 nm. | B | 8.44 | pIC50 | 3.6 | nM | IC50 | US-10259786-B2. Psychotropic agents and uses thereof (2019) |
| D2 receptor/D(2) dopamine receptor in Mouse (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3427] [GtoPdb: 215] [UniProtKB: P61168] | ||||||||
| ChEMBL | Inhibition of mouse Dopamine receptor D2 | B | 7.64 | pIC50 | 23 | nM | IC50 | J Med Chem (1996) 39: 4692-4703 [PMID:8941382] |
| D2 receptor/D(2) dopamine receptor in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL339] [GtoPdb: 215] [UniProtKB: P61169] | ||||||||
| ChEMBL | Binding affinity measured at the Dopamine receptor D2 by the inhibition of [3H]methylspiperone binding to rat striatum using unlabeled haloperidol for nonspecific binding. | B | 7.72 | pKi | 19 | nM | Ki | J Med Chem (1998) 41: 5402-5409 [PMID:9876110] |
| ChEMBL | Receptor Binding Assay: D2 receptor binding was determined as described by Creese et al. (Eur. J. Pharmacol., 60:55-66, 1979) on rat brain striatal membrane preparation using [3H]spiperone (0.4-1.3 nM) as ligand. Non-specific binding was determined in the presence of 1 μM (+) butaclamol. | B | 7.89 | pKi | 13 | nM | Ki | US-8802672-B2. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands (2014) |
| ChEMBL | In vitro ability to displace [3H]spiperone binding from dopamine receptor D2 in rat striatal membrane. | B | 8.09 | pKi | 8.13 | nM | Ki | J Med Chem (1999) 42: 2774-2797 [PMID:10425088] |
| ChEMBL | Affinity against Dopamine receptor D2 | B | 8.09 | pKi | 8.13 | nM | Ki | J Med Chem (2000) 43: 4678-4693 [PMID:11101359] |
| ChEMBL | Inhibitory constant against dopamine D2 receptor using 0.2 nM [3H]-spiperone | B | 8.18 | pKi | 6.65 | nM | Ki | J Med Chem (2005) 48: 266-273 [PMID:15634021] |
| ChEMBL | Binding affinity to the dopamine receptor D2L in rat brain membranes | B | 8.29 | pKi | 5.1 | nM | Ki | J Med Chem (1999) 42: 3342-3355 [PMID:10464021] |
| ChEMBL | Displacement of [3H]spiperone from dopamine D2 receptor in CRL:CD(SD)BR-COBS rat striatum by scintillation spectrometry | B | 8.42 | pKi | 3.8 | nM | Ki | J Med Chem (2009) 52: 151-169 [PMID:19072656] |
| ChEMBL | Displacement of [3H]NPA from rat brain Dopamine receptor D2 | B | 8.43 | pKi | 3.71 | nM | Ki | J Med Chem (1996) 39: 143-148 [PMID:8568801] |
| ChEMBL | Displacement of [3H]spiperone from D2 receptor in rat striatum measured after 15 mins by liquid scintillation counting method | B | 8.43 | pKi | 3.7 | nM | Ki | Eur J Med Chem (2020) 207: 112709-112709 [PMID:32877805] |
| ChEMBL | Displacement of [3H]NPA from rat brain Dopamine receptor D2 | B | 8.43 | pKi | 3.7 | nM | Ki | J Med Chem (1996) 39: 143-148 [PMID:8568801] |
| ChEMBL | Displacement of [3H]spiperone from dopamine D2 receptor in rat striatum after 15 mins by liquid scintillation counting analysis | B | 8.43 | pKi | 3.7 | nM | Ki | J Med Chem (2013) 56: 4671-4690 [PMID:23675993] |
| ChEMBL | Displacement of [3H]spiperone from dopamine D2 receptor in Sprague-Dawley rat striatum incubated for 30 mins by liquid scintillation counting analysis | B | 8.43 | pKi | 3.7 | nM | Ki | Eur J Med Chem (2016) 124: 713-728 [PMID:27639363] |
| ChEMBL | Displacement of [3H]-spiperone from dopamine D2 receptor in rat striatum homogenates after 30 mins by liquid scintillation counting | B | 8.43 | pKi | 3.7 | nM | Ki | J Med Chem (2018) 61: 10017-10039 [PMID:30383372] |
| ChEMBL | Displacement of [3H]spiperone from dopaminergic D2 receptor in rat striatum homogenates after 60 mins by liquid scintillation counting | B | 8.44 | pKi | 3.6 | nM | Ki | Bioorg Med Chem Lett (2015) 25: 5299-5305 [PMID:26483200] |
| ChEMBL | Displacement of [3H]spiperone from dopamine D2 receptor in rat brain | B | 8.51 | pKi | 3.1 | nM | Ki | Bioorg Med Chem (2007) 15: 7361-7367 [PMID:17869521] |
| ChEMBL | Compound was evaluated for its binding affinity with Dopamine receptor D2 using membranes prepared from rat striatum | B | 8.51 | pKi | 3.1 | nM | Ki | J Med Chem (1998) 41: 1997-2009 [PMID:9622541] |
| ChEMBL | The binding affinity was measured on dopamine receptor D2 in rat brain tissue | B | 8.55 | pKi | 2.8 | nM | Ki | J Med Chem (1992) 35: 552-558 [PMID:1346653] |
| ChEMBL | Displacement of [3H]spiperone from dopamine D2 receptor in Sprague-Dawley rat striatum homogenate after 30 mins by liquid scintillation counting | B | 8.55 | pKi | 2.8 | nM | Ki | Eur J Med Chem (2014) 74: 427-439 [PMID:24487191] |
| ChEMBL | Displacement of [3H]spiperone from dopamine D2 receptor in rat striatum | B | 8.55 | pKi | 2.8 | nM | Ki | Medchemcomm (2015) 6: 831-838 |
| ChEMBL | Affinity for Dopamine receptor D2 | B | 8.68 | pKi | 2.1 | nM | Ki | Bioorg Med Chem Lett (1998) 8: 983-988 [PMID:9871525] |
| ChEMBL | Ability to displace [3H]spiperone from D2 dopamine receptor isolated from the striata of male Wistar rats | B | 8.74 | pKi | 1.8 | nM | Ki | Bioorg Med Chem Lett (1995) 5: 1245-1250 |
| ChEMBL | Affinity for dopamine receptor D2 binding sites by its ability to displace [3H]spiperone from rat striatum. | B | 7.43 | pIC50 | 37.5 | nM | IC50 | J Med Chem (1995) 38: 1119-1131 [PMID:7707315] |
| ChEMBL | In vitro affinity towards D2 receptor using [3H]spiroperidol as radioligand in striatum | B | 7.43 | pIC50 | 37 | nM | IC50 | J Med Chem (1994) 37: 2308-2314 [PMID:7914536] |
| ChEMBL | Binding affinity towards Dopamine receptor D2 was determined in rat striatum using [3H]- spiperone as radioligand | B | 7.43 | pIC50 | 37 | nM | IC50 | J Med Chem (1996) 39: 4044-4057 [PMID:8831770] |
| ChEMBL | Compound was measured for affinity at dopamine receptor D2 labeled with [3H]spiroperidol radioligand in striatum tissue | B | 7.52 | pIC50 | 30 | nM | IC50 | J Med Chem (1991) 34: 1068-1072 [PMID:1672156] |
| ChEMBL | Inhibition of [3H]methylspiperone binding to rat striatal membrane Dopamine receptor D2 | B | 7.56 | pIC50 | 27.4 | nM | IC50 | J Med Chem (1998) 41: 5402-5409 [PMID:9876110] |
| ChEMBL | Compound was tested for the inhibition of [3H]spiperone binding to dopamine receptor D2 | B | 8.4 | pIC50 | 4 | nM | IC50 | J Med Chem (1992) 35: 1092-1101 [PMID:1348090] |
| D3 receptor/D(3) dopamine receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL234] [GtoPdb: 216] [UniProtKB: P35462] | ||||||||
| GtoPdb | - | - | 7 | pKi | - | - | - | J Pharmacol Exp Ther (1995) 275: 885-898 [PMID:7473180] |
| ChEMBL | Binding affinity to dopamine D3 receptor (unknown origin) by PDSP assay | B | 7 | pKi | 100 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| ChEMBL | Binding affinity measured at the Dopamine receptor D3 by the inhibition of [3H]YM-09151-2 binding to human recombinant CCL 1.3 cells using unlabeled 7-OH-DPAT for nonspecific binding. | B | 7.51 | pKi | 31 | nM | Ki | J Med Chem (1998) 41: 5402-5409 [PMID:9876110] |
| ChEMBL | Displacement of [3H]spiperone from human dopamine D3 receptor | B | 7.79 | pKi | 16.22 | nM | Ki | Bioorg Med Chem Lett (2009) 19: 6059-6062 [PMID:19796944] |
| ChEMBL | Inhibition of [125I]iodosulpiride binding to human Dopamine receptor D3 | B | 7.8 | pKi | 16 | nM | Ki | J Med Chem (2005) 48: 1709-1712 [PMID:15771415] |
| ChEMBL | Binding affinity to dopamine D3 receptor (unknown origin) | B | 7.84 | pKi | 14.3 | nM | Ki | Bioorg Med Chem Lett (2021) 40: 127909-127909 [PMID:33705900] |
| ChEMBL | Binding affinity towards human dopamine receptor D3 | B | 7.85 | pKi | 14 | nM | Ki | J Med Chem (2001) 44: 477-501 [PMID:11170639] |
| ChEMBL | Binding affinity towards human Dopamine receptor D3 | B | 7.89 | pKi | 13 | nM | Ki | J Med Chem (2004) 47: 1303-1314 [PMID:14998318] |
| ChEMBL | Displacement of [3H]spiperone from human dopamine D3 receptor expressed in CHO cells | B | 8 | pKi | 10 | nM | Ki | J Med Chem (2007) 50: 5103-5108 [PMID:17880057] |
| ChEMBL | Binding affinity to human cloned dopamine D3 receptor | B | 8.02 | pKi | 9.6 | nM | Ki | Bioorg Med Chem (2008) 16: 7291-7301 [PMID:18595716] |
| ChEMBL | DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) | B | 8.09 | pKi | 8.04 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | Displacement of [3H]7OH-DPAT from dopamine D3 receptor expressed in Sf9 cells by scintillation spectrometry | B | 8.17 | pKi | 6.7 | nM | Ki | J Med Chem (2009) 52: 151-169 [PMID:19072656] |
| ChEMBL | Binding affinity to dopamine D3 receptor (unknown origin) | B | 8.17 | pKi | 6.7 | nM | Ki | J Med Chem (2014) 57: 9578-9597 [PMID:25343529] |
| ChEMBL | DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) | B | 7.62 | pIC50 | 24 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| ChEMBL | Antagonist activity at human dopamine D3 receptor expressed in pathHunter cells assessed as inhibition of dopamine-induced beta-arrestin translocation activity preincubated for 30 mins followed by dopamine addition and measured after 90 to 180 min by pathHunter microplate based TANGO assay | F | 7.62 | pIC50 | 24 | nM | IC50 | J Med Chem (2023) 66: 10060-10079 [PMID:37421373] |
| D3 receptor/D(3) dopamine receptor in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3138] [GtoPdb: 216] [UniProtKB: P19020] | ||||||||
| ChEMBL | Displacement of [3H] 7-OH-DPAT from dopamine D3 receptor in rat olfactory tubercle homogenates after 60 mins by liquid scintillation counting | B | 7.5 | pKi | 31.9 | nM | Ki | J Med Chem (2018) 61: 10017-10039 [PMID:30383372] |
| ChEMBL | Displacement of [3H]7-OH-DPAT from dopamine D3 receptor in rat olfactory tubercle | B | 7.82 | pKi | 15.1 | nM | Ki | Medchemcomm (2015) 6: 831-838 |
| ChEMBL | Receptor Binding Assay: Binding assays were carried out on rat recombinant D3 receptors (Perkin-Elmer, Cat. No. 6110139) expressed in Sf9 cells using [3H]spiperone (0.44-1.49 nM) as ligand and haloperidol (10 μM) for determination of non-specific binding. The assay was performed according to the supplier's assay protocol (Cat. No.: 3110139). | B | 7.89 | pKi | 13 | nM | Ki | US-8802672-B2. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands (2014) |
| ChEMBL | Displacement of [3H]7-OH-DPA from dopamine D3 receptor in Sprague-Dawley rat olfactory tubercle homogenate after 60 mins by liquid scintillation counting | B | 8 | pKi | 10.1 | nM | Ki | Eur J Med Chem (2014) 74: 427-439 [PMID:24487191] |
| ChEMBL | Displacement of [3H]7-OH-DPAT from dopamine D3 receptor in rat olfactory tubercle after 60 mins by liquid scintillation counting analysis | B | 8.01 | pKi | 9.7 | nM | Ki | J Med Chem (2013) 56: 4671-4690 [PMID:23675993] |
| D4 receptor/D(4) dopamine receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL219] [GtoPdb: 217] [UniProtKB: P21917] | ||||||||
| ChEMBL | Binding affinity to dopamine D4 receptor (unknown origin) by PDSP assay | B | 7 | pKi | 100 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| ChEMBL | Binding affinity towards human dopamine receptor D4 | B | 7.8 | pKi | 16 | nM | Ki | J Med Chem (2001) 44: 477-501 [PMID:11170639] |
| ChEMBL | Binding affinity towards human dopamine-4.2 receptor | B | 7.8 | pKi | 16 | nM | Ki | J Med Chem (2004) 47: 1303-1314 [PMID:14998318] |
| ChEMBL | Displacement of [3H]spiperone from human dopamine D4.4 receptor expressed in CHO cells | B | 8 | pKi | 10 | nM | Ki | J Med Chem (2007) 50: 5103-5108 [PMID:17880057] |
| ChEMBL | Binding affinity to human cloned dopamine D4 receptor | B | 8.07 | pKi | 8.5 | nM | Ki | Bioorg Med Chem (2008) 16: 7291-7301 [PMID:18595716] |
| ChEMBL | Ability to inhibit the binding of [3H]spiperone to the Dopamine receptor D4 in COS7 cells | B | 8.15 | pKi | 7 | nM | Ki | J Med Chem (1995) 38: 708-714 [PMID:7861418] |
| ChEMBL | Binding affinity measured at the Dopamine receptor D4 by the inhibition of [3H]spiperone binding to human recombinant CHO cells using unlabeled haloperidol for nonspecific binding. | B | 8.21 | pKi | 6.2 | nM | Ki | J Med Chem (1998) 41: 5402-5409 [PMID:9876110] |
| glycine receptor α1 subunit/Glycine receptor subunit alpha-1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5845] [GtoPdb: 423] [UniProtKB: P23415] | ||||||||
| ChEMBL | Potentiation of human GlyR-alpha1 expressed in Xenopus laevis oocytes assessed as induction of glycine-activated currents after 1 to 4 days by two-electrode voltage clamp assay | B | 6.49 | pEC50 | 320 | nM | EC50 | J Med Chem (2015) 58: 2958-2966 [PMID:25790278] |
| H1 receptor/Histamine H1 receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL231] [GtoPdb: 262] [UniProtKB: P35367] | ||||||||
| ChEMBL | Binding affinity to H1 histamine receptor (unknown origin) by PDSP assay | B | 7 | pKi | 100 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| ChEMBL | Binding affinity towards human H1 receptor | B | 7.06 | pKi | 88 | nM | Ki | J Med Chem (2001) 44: 477-501 [PMID:11170639] |
| ChEMBL | Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor | B | 7.48 | pKi | 33 | nM | Ki | J Med Chem (2005) 48: 1709-1712 [PMID:15771415] |
| ChEMBL | Binding affinity to H1 histamine receptor (unknown origin) | B | 7.7 | pKi | 20 | nM | Ki | Bioorg Med Chem Lett (2021) 31: 127681-127681 [PMID:33189775] |
| ChEMBL | Binding affinity to human cloned histamine H1 receptor | B | 7.72 | pKi | 19 | nM | Ki | Bioorg Med Chem (2008) 16: 7291-7301 [PMID:18595716] |
| GtoPdb | - | - | 7.8 | pKi | - | - | - |
Psychopharmacology (Berl.) (1996) 124: 57-73 [PMID:8935801]; Neuropsychopharmacology (2003) 28: 519-26 [PMID:12629531] |
| ChEMBL | Binding Assay: Binding assay using 5-HT2A, Dopamine D2, SERT, αA1, 5-HT2C and H1 Receptors. | B | 7.85 | pKi | 14 | nM | Ki | US-8598119-B2. Methods and compositions for sleep disorders and other disorders (2013) |
| ChEMBL | DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine) | B | 8.54 | pKi | 2.87 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | Binding affinity towards human histamine H1 receptor | B | 8.59 | pKi | 2.6 | nM | Ki | J Med Chem (2004) 47: 1303-1314 [PMID:14998318] |
| ChEMBL | Antagonistic activity at histamine1 receptor (unknown origin) after 10 mins by FLIPR assay | B | 6.06 | pIC50 | 868 | nM | IC50 | Bioorg Med Chem Lett (2016) 26: 3141-3147 [PMID:27173799] |
| ChEMBL | Antagonistic activity at histamine 1 receptor (unknown origin) after 10 mins by FLIPR assay | F | 6.34 | pIC50 | 454 | nM | IC50 | Bioorg Med Chem Lett (2018) 28: 606-611 [PMID:29395980] |
| ChEMBL | Antagonist activity at histamine H1 receptor (unknown origin) after 10 mins by calcium 5 dye based FLIPR assay | F | 6.34 | pIC50 | 454 | nM | IC50 | Eur J Med Chem (2018) 145: 74-85 [PMID:29324345] |
| ChEMBL | DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine) | B | 7.6 | pIC50 | 25 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| H1 receptor/Histamine H1 receptor in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4701] [GtoPdb: 262] [UniProtKB: P31390] | ||||||||
| ChEMBL | Receptor Binding Assay: Histamine H1: (1) The prepared membrane was applied with appropriate amount of buffer, and homogenizer was used for evenly dispersing. 15 tubes were mixed into a 100 ml container, and appropriate amount of buffer (potassium dihydrogen phosphate 1.36 g, 0.1 mol/L sodium hydroxide 79 ml, metered to 200 ml with double-distilled water) was added to give 50 ml of membrane suspension, which was reserved for future use. (2) 100 uL of membrane preparation was added into each reaction tube. (3) 100 uL of buffer was added into the total binding tube (TB), 100 uL of promethazine (final concentration 10-5M) was added into the nonspecific binding tube (NB), 100 uL of the test compound (final concentration 10-5M) was added into the specific binding tube (SB) of each test compound. (4) 10 uL of radioactive ligand 3H-pyrilamine was respectively added into each reaction tube (2 parallel tubes were used for each reaction tube, and each of them was placed on ice when adding sample). (5) Each of the reaction tubes was incubated at 30° C. for 60 min. After the reaction was completed, the bound ligands were rapidly filtered under reduced pressure, and the ice-chilled assay buffer was used for adequate washing. The filter was taken out and put into a 3 ml scintillation vial, and 2 ml of toluene scintillation solution was added and blended. 2* Isotope ligand [3H]-5-CT (85.4 Ci/mmol) was purchased from PerkinElmer Company; (+-)-pindolol was purchased from RBI Company; GF/C glass fiber filter paper was purchased from Whatman Company; Tris was imported and divided into aliquots; PPO and POPOP were purchased from Shanghai No. 1 Reagent Factory; liposoluble scintillation cocktail was purchased from Shanghai Reagent Factory. Beckman LS-6500 Multi-function Liquid Scintillation Counter was used. | B | 6.77 | pKi | 169 | nM | Ki | US-10501452-B2. Lactam compound derivative and application thereof (2019) |
| ChEMBL | Displacement of [3H]mepyramine from H1R in rat brain | B | 7.1 | pIC50 | 80 | nM | IC50 | Proc Natl Acad Sci U S A (2007) 104: 3456-3459 [PMID:17360666] |
| Histamine H1 receptor in Guinea pig (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3943] [UniProtKB: P31389] | ||||||||
| ChEMBL | Displacement of [3H]-mepyramine from histamine H1 receptor in guinea pig cerebellum homogenates incubated for 60 mins by liquid scintillation counting | B | 7.34 | pKi | 46.2 | nM | Ki | J Med Chem (2018) 61: 10017-10039 [PMID:30383372] |
| ChEMBL | Displacement of [3H]mepyramine from histamine H1 receptor in guinea pig cerebellum | B | 7.39 | pKi | 41.2 | nM | Ki | Medchemcomm (2015) 6: 831-838 |
| ChEMBL | Displacement of [3H]mepyramine from histamine H1 receptor in guinea pig cerebellum homogenates after 60 mins by liquid scintillation counting | B | 7.42 | pKi | 38.3 | nM | Ki | Bioorg Med Chem Lett (2015) 25: 5299-5305 [PMID:26483200] |
| ChEMBL | Displacement of [3H]mepyramine from histamine H1 receptor in guinea pig cerebellum homogenate after 60 mins by liquid scintillation counting | B | 7.64 | pKi | 22.9 | nM | Ki | Eur J Med Chem (2014) 74: 427-439 [PMID:24487191] |
| ChEMBL | Displacement of [3H]mepyramine from histamine H1 receptor in guinea pig cerebellum after 60 mins by liquid scintillation counting analysis | B | 7.66 | pKi | 21.7 | nM | Ki | J Med Chem (2013) 56: 4671-4690 [PMID:23675993] |
| ChEMBL | Displacement of [3H]pyrilamine from histaminergic H1 receptor guinea pig cerebellum | B | 8.1 | pKi | 7.94 | nM | Ki | J Med Chem (2007) 50: 5103-5108 [PMID:17880057] |
| H2 receptor/Histamine H2 receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1941] [GtoPdb: 263] [UniProtKB: P25021] | ||||||||
| ChEMBL | DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine) | B | 5.84 | pKi | 1458 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine) | B | 5.83 | pIC50 | 1483 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| H3 receptor/Histamine H3 receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL264] [GtoPdb: 264] [UniProtKB: Q9Y5N1] | ||||||||
| ChEMBL | Binding affinity to histamine H3 receptor (unknown origin) | B | 5.96 | pKi | 1105.5 | nM | Ki | Bioorg Med Chem Lett (2021) 40: 127909-127909 [PMID:33705900] |
| Multidrug and toxin extrusion/Multidrug and toxin extrusion protein 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1743126] [GtoPdb: 1216] [UniProtKB: Q96FL8] | ||||||||
| ChEMBL | Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay | B | 5.8 | pIC50 | 1600 | nM | IC50 | J Med Chem (2013) 56: 781-795 [PMID:23241029] |
| M1 receptor/Muscarinic acetylcholine receptor M1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL216] [GtoPdb: 13] [UniProtKB: P11229] | ||||||||
| ChEMBL | Binding affinity towards human M1 receptor. | B | 5.3 | pKi | >5000 | nM | Ki | J Med Chem (2001) 44: 477-501 [PMID:11170639] |
| ChEMBL | Binding affinity to human cloned muscarinic M1 receptor | B | 5.55 | pKi | 2800 | nM | Ki | Bioorg Med Chem (2008) 16: 7291-7301 [PMID:18595716] |
| ChEMBL | Binding affinity to M1 receptor (unknown origin) by PDSP assay | B | 6 | pKi | >1000 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| M2 receptor/Muscarinic acetylcholine receptor M2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL211] [GtoPdb: 14] [UniProtKB: P08172] | ||||||||
| ChEMBL | Binding affinity to M2 receptor (unknown origin) by PDSP assay | B | 6 | pKi | >1000 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| M3 receptor/Muscarinic acetylcholine receptor M3 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL245] [GtoPdb: 15] [UniProtKB: P20309] | ||||||||
| ChEMBL | Binding affinity to M3 receptor (unknown origin) by PDSP assay | B | 6 | pKi | >1000 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| ChEMBL | Antagonist activity at M3 receptor (unknown origin) after 10 mins by calcium 5 dye based FLIPR assay | F | 4 | pIC50 | >100000 | nM | IC50 | Eur J Med Chem (2018) 145: 74-85 [PMID:29324345] |
| M4 receptor/Muscarinic acetylcholine receptor M4 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1821] [GtoPdb: 16] [UniProtKB: P08173] | ||||||||
| ChEMBL | Binding affinity to M4 receptor (unknown origin) by PDSP assay | B | 6 | pKi | >1000 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| M5 receptor/Muscarinic acetylcholine receptor M5 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2035] [GtoPdb: 17] [UniProtKB: P08912] | ||||||||
| ChEMBL | Binding affinity to M5 receptor (unknown origin) by PDSP assay | B | 6 | pKi | >1000 | nM | Ki | Medchemcomm (2012) 3: 580-583 |
| Norepinephrine transporter in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL304] [UniProtKB: Q9WTR4] | ||||||||
| ChEMBL | Inhibition of [3H]nisoxetine binding to rat Norepinephrine transporter | B | 5.26 | pKi | >5454 | nM | Ki | J Med Chem (2005) 48: 1709-1712 [PMID:15771415] |
| Plasmodium falciparum (target type: ORGANISM) [ChEMBL: CHEMBL364] | ||||||||
| ChEMBL | Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay | F | 4.9 | pIC50 | 12589.25 | nM | IC50 | Nat Chem Biol (2009) 5: 765-771 [PMID:19734910] |
| ChEMBL | Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay | F | 4.9 | pIC50 | 12589.25 | nM | IC50 | Nat Chem Biol (2009) 5: 765-771 [PMID:19734910] |
| ChEMBL | Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay | F | 4.9 | pIC50 | 12589.25 | nM | IC50 | Nat Chem Biol (2009) 5: 765-771 [PMID:19734910] |
| ChEMBL | Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay | F | 4.9 | pIC50 | 12589.25 | nM | IC50 | Nat Chem Biol (2009) 5: 765-771 [PMID:19734910] |
| ChEMBL | Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay | F | 5 | pIC50 | 10000 | nM | IC50 | Nat Chem Biol (2009) 5: 765-771 [PMID:19734910] |
| ChEMBL | Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay | F | 5 | pIC50 | 10000 | nM | IC50 | Nat Chem Biol (2009) 5: 765-771 [PMID:19734910] |
| sigma non-opioid intracellular receptor 1/Sigma non-opioid intracellular receptor 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL287] [GtoPdb: 2552] [UniProtKB: Q99720] | ||||||||
| ChEMBL | Binding affinity measured at the sigma receptor by the inhibition of [3H]-3-PPP binding to guinea pig cerebellum using unlabeled 3-PPP for nonspecific binding. | B | 5.37 | pKi | 4300 | nM | Ki | J Med Chem (1998) 41: 5402-5409 [PMID:9876110] |
| SERT/Sodium-dependent serotonin transporter in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL228] [GtoPdb: 928] [UniProtKB: P31645] | ||||||||
| ChEMBL | Binding affinity to human SERT | B | 5.85 | pKi | 1400 | nM | Ki | Bioorg Med Chem (2008) 16: 7291-7301 [PMID:18595716] |
| ChEMBL | Binding Assay: Binding assay using 5-HT2A, Dopamine D2, SERT, αA1, 5-HT2C and H1 Receptors. | B | 6 | pKi | 1000 | nM | Ki | US-8598119-B2. Methods and compositions for sleep disorders and other disorders (2013) |
| Organic cation transporter 2/Solute carrier family 22 member 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1743122] [GtoPdb: 1020] [UniProtKB: O15244] | ||||||||
| ChEMBL | Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay | B | 4.96 | pIC50 | 11000 | nM | IC50 | J Med Chem (2013) 56: 781-795 [PMID:23241029] |
| Transporter in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL6184] [UniProtKB: Q63380] | ||||||||
| ChEMBL | Binding affinity to rat NET | B | 4.55 | pKi | 28000 | nM | Ki | Bioorg Med Chem (2008) 16: 7291-7301 [PMID:18595716] |
| Voltage-dependent L-type calcium channel subunit alpha-1C in Guinea pig (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2366456] [UniProtKB: O35505] | ||||||||
| ChEMBL | Inhibition of calcium current (ICaL) measured using whole-cell patch clamp experiments in isolated guinea pig ventricular myocytes | F | 4.14 | pIC50 | 73000 | nM | IC50 | Cardiovasc Res (2011) 91: 53-61 [PMID:21300721] |
| ChEMBL | Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes | F | 4.14 | pIC50 | 73000 | nM | IC50 | J Appl Toxicol (2012) 32: 858-866 [PMID:22761000] |
| Kv11.1/Voltage-gated inwardly rectifying potassium channel KCNH2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL240] [GtoPdb: 572] [UniProtKB: Q12809] | ||||||||
| ChEMBL | DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole) | B | 5.46 | pKi | 3432.8 | nM | Ki | DrugMatrix in vitro pharmacology data |
| ChEMBL | Binding affinity to human ERG expressed in HEK293 cells by whole cell patch clamp method | B | 6.04 | pKi | 920 | nM | Ki | J Med Chem (2009) 52: 151-169 [PMID:19072656] |
| ChEMBL | DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole) | B | 5.38 | pIC50 | 4190.1 | nM | IC50 | DrugMatrix in vitro pharmacology data |
| ChEMBL | Inhibition of human ERG | B | 5.88 | pIC50 | 1330 | nM | IC50 | Bioorg Med Chem Lett (2020) 30: 127027-127027 [PMID:32122737] |
| ChEMBL | Inhibition of human ERG by auomated patch clamp assay | B | 5.88 | pIC50 | 1330 | nM | IC50 | Eur J Med Chem (2018) 145: 74-85 [PMID:29324345] |
| ChEMBL | Inhibition of human ERG | B | 5.88 | pIC50 | 1330 | nM | IC50 | Bioorg Med Chem (2017) 25: 4904-4916 [PMID:28774576] |
| ChEMBL | Inhibition of human ERG after 10 mins | B | 5.97 | pIC50 | 1070 | nM | IC50 | Bioorg Med Chem Lett (2016) 26: 3141-3147 [PMID:27173799] |
| ChEMBL | Inhibition of human ERG | B | 6.11 | pIC50 | 778 | nM | IC50 | Medchemcomm (2015) 6: 831-838 |
| ChEMBL | Inhibition of human ERG expressed in HEK293 cells by electrophysiology assay | B | 6.24 | pIC50 | 581 | nM | IC50 | J Med Chem (2013) 56: 4671-4690 [PMID:23675993] |
| ChEMBL | Inhibitory concentration against IKr potassium channel | B | 6.59 | pIC50 | 260 | nM | IC50 | Bioorg Med Chem Lett (2004) 14: 4771-4777 [PMID:15324906] |
| ChEMBL | Inhibition of human ERG expressed in HEK293 cells at -50 mV holding potential by patch clamp assay | B | 6.78 | pIC50 | 167.1 | nM | IC50 | J Med Chem (2018) 61: 10017-10039 [PMID:30383372] |
| ChEMBL | Inhibition of human ERG by automated patch method relative to control | B | 6.78 | pIC50 | 167 | nM | IC50 | Bioorg Med Chem Lett (2021) 40: 127909-127909 [PMID:33705900] |
| ChEMBL | Inhibition of human ERG expressed in HEK293 cells by whole-cell patch clamp method | B | 6.78 | pIC50 | 167 | nM | IC50 | Eur J Med Chem (2020) 207: 112709-112709 [PMID:32877805] |
| ChEMBL | K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.1 | F | 6.79 | pIC50 | 163 | nM | IC50 | J Med Chem (2002) 45: 3844-3853 [PMID:12190308] |
| ChEMBL | Inhibition of human ERG in MCF7 cells | B | 6.79 | pIC50 | 162.18 | nM | IC50 | Eur J Med Chem (2009) 44: 1926-1932 [PMID:19110341] |
| ChEMBL | Inhibition of human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel) in open state | F | 6.79 | pIC50 | 162.18 | nM | IC50 | Bioorg Med Chem Lett (2005) 15: 1737-1741 [PMID:15745831] |
| ChEMBL | Inhibition of human Potassium channel HERG expressed in mammalian cells | B | 6.82 | pIC50 | 151.36 | nM | IC50 | Bioorg Med Chem Lett (2003) 13: 2773-2775 [PMID:12873512] |
| ChEMBL | Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique | B | 6.82 | pIC50 | 151.36 | nM | IC50 | Bioorg Med Chem (2008) 16: 6252-6260 [PMID:18448342] |
| ChEMBL | Inhibition of hERG K channel | F | 6.82 | pIC50 | 150 | nM | IC50 | Cardiovasc Res (2011) 91: 53-61 [PMID:21300721] |
| ChEMBL | Inhibition of human ERG channel | B | 6.83 | pIC50 | 148 | nM | IC50 | J Med Chem (2009) 52: 4266-4276 [PMID:19534531] |
| ChEMBL | Inhibition of human ERG channel | B | 6.83 | pIC50 | 148 | nM | IC50 | J Med Chem (2009) 52: 4266-4276 [PMID:19534531] |
| ChEMBL | Inhibition of human ERG | B | 6.83 | pIC50 | 147.91 | nM | IC50 | Eur J Med Chem (2011) 46: 618-630 [PMID:21185626] |
| 5-HT1F receptor in Human [GtoPdb: 5] [UniProtKB: P30939] | ||||||||
| GtoPdb | - | - | 5.9 | pKi | - | - | - | Psychopharmacology (Berl.) (1996) 124: 57-73 [PMID:8935801] |
ChEMBL data shown on this page come from version 36:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]
